In preclinical models, novel small molecule orally available RNA destabilizers employ a unique mechanism to specifically destabilize HBV RNA transcripts, leading to reductions in HBV proteins, including HBsAg.

HBV RNA destabilizers could potentially selectively impact HBV but not other RNA or DNA viruses and could as well demonstrate pan-genotypic antiviral activity. In addition, HBV RNA destabilizers have shown additive effects when provided in combination with anti-HBV agents having distinct mechanisms of action.

Our long-term strategy is to develop an all-oral combination treatment regimen to cure HBV which could potentially include an oral HBV RNA destabilizer in combination with a capsid inhibitor and an approved NA. AB-161 is currently in IND-enabling studies.